Cartesian Therapeutics (RNAC) Income from Continuing Operations (2015 - 2026)
Cartesian Therapeutics' (RNAC) quarterly Income from Continuing Operations came in at 26642000.0 in Q1 2026, down 31.95% year-on-year from 39150554.73 in Q1 2025, and up 64.59% on a QoQ basis from 75244000.0 in Q4 2025.
Cartesian Therapeutics (RNAC) Income from Continuing Operations (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of Income from Continuing Operations data on file, last reported at 26642000.0 in Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 31.95% year-over-year to 26642000.0 in Q1 2026; TTM through Mar 2026 was 163578000.0, a 74.36% decrease from a year earlier, with the FY2025 full-year figure at 130295000.0, down 68.26% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 26642000.0, up from 75244000.0 in the prior quarter.
- Over the last five years, Income from Continuing Operations for RNAC reached as high as 13352000.0 in Q2 2022 and fell as low as 196658000.0 in Q4 2023.
- Historically, Income from Continuing Operations has averaged 29627705.88 across 5 years, with a median of 20191000.0 in 2025.
- Across the five-year window, Income from Continuing Operations surged 5275.19% in 2022 and sank 3437.15% in 2023, its largest moves.
- Year by year, Income from Continuing Operations stood at 5893000.0 in 2022, then sank by 3437.15% to 196658000.0 in 2023, then jumped by 87.14% to 25288000.0 in 2024, then tumbled by 197.55% to 75244000.0 in 2025, then soared by 64.59% to 26642000.0 in 2026.
- Per Business Quant data, the three most recent Income from Continuing Operations figures were 26642000.0 in Q1 2026, 75244000.0 in Q4 2025, and 24605000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Cartesian Therapeutics | 210.28 Mn | 210.28 Mn | - | -26.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.64 Mn |
| Dec 31, 2025 | -75.24 Mn |
| Sep 30, 2025 | -24.61 Mn |
| Jun 30, 2025 | -37.09 Mn |
| Mar 31, 2025 | -20.19 Mn |
| Dec 31, 2024 | -25.29 Mn |
| Sep 30, 2024 | -30.21 Mn |
| Jun 30, 2024 | -18.13 Mn |
| Mar 31, 2024 | -24.88 Mn |
| Dec 31, 2023 | -196.66 Mn |
| Sep 30, 2023 | -9.00 Mn |
| Jun 30, 2023 | -18.00 Mn |
| Mar 31, 2023 | -19.18 Mn |
| Dec 31, 2022 | 5.89 Mn |
| Sep 30, 2022 | -7.89 Mn |
| Jun 30, 2022 | 13.35 Mn |
| Mar 31, 2022 | 10.08 Mn |
| Dec 31, 2021 | 12.24 Mn |
| Sep 30, 2021 | -17.89 Mn |
| Jun 30, 2021 | -258,000.00 |